I think you're making assumptions about the missed opportunities, and also about the level of control by management. There are many external circumstances beyond their control, such as lawsuits and pandemics.
I do believe that the usefulness of the drug is the ultimate factor in this company's value, and while it's taking longer than hoped for and expected, we're in a good situation now to see a big increase in valuation.